Proinflammatory biomarkers and platelet aggregation activity in patients with coronary artery disease

Aim. To determine concentrations and identify the relationship of biomarkers (endocan / cell-specific molecule-1, fatty acid binding protein 4 (FABP 4), placental growth factor (PlGF), oncostatin M), with parameters of collageninduced platelet aggregation in patients with coronary artery disease (CAD).

Materials and methods. In patients with CAD (n = 51), serum levels of endocan, FABP 4, PlGF, oncostatin M, and platelet aggregation indices (collagen at concentrations of 2 and 10 mmol / l) were determined. Patients were divided into groups with and without high residual platelet reactivity (HRPR). Correlation coefficients between concentrations of proinflammatory biomarkers and platelet aggregation indices were determined in patients of both groups.

Results. In patients with HRPR, the concentrations of endocan and PlGF were significantly higher, and the concentrations of FABP4 and oncostatin M were lower than in the first group. In patients with HRPR, a correlation was found between the concentration of endocan and the degree of platelet aggregation in the presence of 2 mmol

/ l of collagen (ρ = 0.48; p = 0.01), between the concentration of PlGF and the degree of platelet aggregation in the presence of 10 mmol / l of collagen (ρ = 0.58; p = 0.01), as well as between the concentration of FABP 4 and the size of aggregates at both collagen concentrations (ρ = 0.42; p = 0.03) and (ρ = 0.70; p = 0.01) and the degree of platelet aggregation in the presence of 10 mmol / l of collagen (ρ = 0.43; p = 0.01).

Conclusion. In all examined CAD patients, regardless of the residual platelet reactivity, the levels of endocan and FABP 4 increased compared to the reference values. In patients with HRPR, the content of parameters (endocan, PlGF) contributing to plaque growth was elevated, and in patients without HRPR, the levels of platelet-activating factors (FABР 4, oncostatin M) were increased, which determines a personalized approach to prescribing therapy for these groups of patients. In patients with CAD, platelet aggregation indices were associated with concentrations of proinflammatory biomarkers (endocan, PlGF, and FABP 4), which contribute to the development of endothelial dysfunction.

1. Stone G.W., Witzenbichler B., Weisz G., Rinaldi M.J., Neumann F.-J., Metzger D.C. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–623. DOI: 10.1016/S0140-6736(13)61170-8.

2. Мирзаев К.Б., Андреев Д.А., Сычев Д.А. Оценка агрегации тромбоцитов в клинической практике. Рациональная фармакотерапия в кардиологии. 2015;11(1):85–91. DOI: 10.20996/1819-6446-2015-11-1-85-91.

3. Трубачева О.А., Суслова Т.Е., Гусакова А.М., Кологривова И.В., Шнайдер О.Л., Завадовский К.В. и др. Высокая остаточная агрегационная активность тромбоцитов у пациентов с ишемической болезнью сердца: новый методический подход к выявлению. Бюллетень сибирской медицины. 2021;20(2):113–119. DOI: 10.20538/1682-0363-2021-2-113-119.

4. Барбараш О.Л., Комаров А.Л., Панченко Е.П., Староверов И.И., Шахнович Р.М., Явелов И.С. Евразийские клинические рекомендации по диагностике и лечению острого коронарного синдрома без подъема сегмента ST. Евразийский кардиологический журнал. 2021;(4):6–59. DOI: 10.38109/2225-1685-2021-4-6-59.

5. Tariket S., Sut C., Arthaud C.A., Eyraud M.A., Meneveaux A., Laradi S. et al. Modeling the effect of platelet concentrate supernatants on endothelial cells: focus on endocan/ESM-1. Transfusion. 2018;58(2):439–445. DOI: 10.1111/trf.14450.

6. Sviridova S.P., Somonova O.V., Kashiya Sh.R., Obukhova O.A., Sotnikov A.V. The role of platelets in inflammation and immunity. Research’n Practical Medicine Journal. 2018;5(3):40–52. DOI: 10.17709/2409-2231-2018-5-3-4.

7. Wallace P.M., MacMaster J.F., Rillema J.R., Peng J., Burstein S.A., Shoyab M. Thrombocytopoietic properties of oncostatin M. Blood. 1995;86(4):1310–1315. DOI: 10.1182/blood.V86.4.1310.bloodjournal8641310.

8. Fossey S.L., Bear M.D., Kisseberth W.C., Pennell M., London C.A. Oncostatin M promotes STAT3 ctivation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer. 2011;11:125. DOI: 10.1186/1471-2407-11-125.

9. Smadja D., Gaussem P., Roncal C., Fischer A.M., Emmerich J., Darnige L. Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus. 2010;19(7):837–843. DOI: 10.1177/0961203309360985.

10. Sharma A., Hijazi Z., Andersson U., Al-Khatib S.M., Lopes R.D., Alexander J.H. Use of biomarkers to predict specific causes of death in patients with atrial fibrillation insights: From the ARISTOTLE trial. Circulation. 2018;138(16):1666– 1676. DOI: 10.1161/CIRCULATIONAHA.118.034125.

11. Liu G., Ding M., Chiuve S.E., Rimm E.B., Franks P.W., Meigs J.B. et al. Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: a 22-year prospective study. Arteriosclerosis, Thrombosis and Vascular Biology. 2016;6(11):2259–2267. DOI:nm10.1161/ATVBAHA.116.308320.

12. Rodríguez-Calvo R., Girona J., Alegret J., Bosquet A., Ibarretxe D., Masana L. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. Journal of Endocrinology. 2017;233(3):173–184. DOI: 10.1530/JOE17-0031.

13. Balta S., Balta I., Mikhailidis D. Endocan: a new marker of endothelial function. Curr. Opin. Cardiol. 2021;36(4):462–468. DOI: 10.1097/HCO.0000000000000867.

14. Kral J.B., Schromaier W.C., Salzmann M., Assinger A. Platelet Interac on with Innate Immune Cells. Transfus Med. Hemother. 2016;43(2):78–88. DOI: 10.1159/000444807.

15. Абдурахманов З.М., Умаров Б.Я., Абдурахманов М.М. Современные биомаркеры эндотелиальной дисфункции при сердечно-сосудистых заболеваниях. Рациональная фармакотерапия в кардиологии. 2021;17(4):612–618. DOI: 10.20996/1819-6446-2021-08-08.

16. Trojnar M., Patro-Małysza J., Kimber-Trojnar Ż., Leszczyńska-Gorzelak B, Mosiewicz J. Associations between fatty acid-binding protein 4–a proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells. 2019;8(3):227. DOI: 0.3390/cells8030227.

17. Ray D.M., Spinelli S.L., O’Brien J.J., Blumberg N., Phipps R.P. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. Bio. Drugs. 2006;20(4):231–241. DOI: 10.2165/00063030-200620040-00004.

18. Туликов М.В., Шевченко О.П., Шевченко А.О., Гагаев А.В., Павлов В.В., Гинзбург Л.М. Плацентарный фактор роста в диагностике и прогнозировании течения ишемической болезни сердца. Вестник Национального медико-хирургического Центра им. Н.И. Пирогова. 2012;7(3):86–89. DOI: 10.17650/1818-8338-2012-3-4-28-32.

19. Li Y., Sun L., Zheng X., Liu J., Zheng R., Lv Y. The clinical value of platelet parameters combined with sFlt-1/PlGF in predicting preeclampsia. Ann Palliat Med. 2021;10(7):7619- 7626. DOI:10.21037/apm-21-1244.

20. Feng Y., Ye D., Wang Z., Pan H., Lu X., Wang M. et al. The role of interleukin-6 family members in cardiovascular diseases. Front. Cardiovasc. Med. 2022;9:818890. DOI: 10.3389/fcvm.2022.818890.

21. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein e. Nat. Med. 2003;9(1):61–67. DOI: 10.1038/nm810.

22. Klingenberg R., Aghlmandi S., Räber L., Gencer B., Nanchen D., Heg D. et al. Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. Eur. Heart J. Acute Cardiovasc. Care. 2018;7(2):129–138. DOI: 10.1177/2048872616684678.